Akadeum Life Sciences, a pioneer in buoyancy-based cell separation technology, announced the successful close of a $20 million+ financing round. The round was led by Michigan Capital Network, with strong participation from Arboretum Ventures, NYBC Ventures, and other investors.
This capital infusion comes at a pivotal moment for Akadeum, following the recent launch of a GMP-compliant product suite designed for use in clinical trials-a critical step in advancing next-generation cell therapies. The company also recently unveiled the integration ability of microbubbles to go into many existing cell therapy manufacturing tools.
“We’re grateful for the support of our investors, who share our belief in a future where everyone can access transformative cell therapies—a future that requires better cell separation technology to unleash its full potential” said Brandon McNaughton, PhD, CEO and Founder of Akadeum.
Also Read: Sanofi Acquires Blueprint Medicines to Boost Immunology Pipeline
The funding will be used to scale commercial operations and especially support customers entering clinical trials. Akadeum has gained strong industry momentum, with growing interest from leading biopharma and partners including Catalent, Charles River Laboratories, ElevateBio, and Lonza, who have featured Akadeum’s technology in recent conference talks and poster sessions.
“Akadeum is delivering some of the most innovative and disruptive technologies we’ve seen in this space,” said Paul D’Amato, CEO and Managing Director at Michigan Capital Network. “With the company recently winning the Disruptor of the Year Award during Advanced Therapies Week, word is spreading about Akadeum’s platform which is redefining how cells are isolated and prepared for therapeutic use. We’re proud to support this next stage of growth.”
SOURCE: PRNewswire